nafamostat has been researched along with Hyperkalemia in 9 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Hyperkalemia: Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "1." | 6.39 | Mechanisms of hyperkalemia caused by nafamostat mesilate. ( Asano, Y; Imai, M; Muto, S, 1995) |
| "It has been reported that continuous intravenous infusion of nafamostat mesilate (FUT) produces hyperkalemia due to reduced urinary excretion of potassium." | 3.68 | [Effect of nafamostat mesilate on the renin-aldosterone system]. ( Hayami, H; Ishida, H; Kono, K; Marukawa, S; Okamoto, T; Ozaki, K, 1992) |
| "1." | 2.39 | Mechanisms of hyperkalemia caused by nafamostat mesilate. ( Asano, Y; Imai, M; Muto, S, 1995) |
| "Nafamostat mesylate was administered with continuous intravenous infusion for an average of 4." | 1.72 | Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study. ( Fujii, K; Hasegawa, N; Itoh, K; Kikuchi, T; Maruki, T; Nakamura, M; Soma, T; Taniyama, D; Yoshifuji, A, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Kodama, K | 1 |
| Imai, T | 1 |
| Asai, Y | 1 |
| Kozu, Y | 1 |
| Hayashi, K | 1 |
| Shimizu, T | 1 |
| Gon, Y | 1 |
| Ootsuka, S | 1 |
| Soma, T | 1 |
| Fujii, K | 1 |
| Yoshifuji, A | 1 |
| Maruki, T | 1 |
| Itoh, K | 1 |
| Taniyama, D | 1 |
| Kikuchi, T | 1 |
| Hasegawa, N | 1 |
| Nakamura, M | 1 |
| Nishimura, H | 1 |
| Yamaya, M | 1 |
| Kurisu, S | 1 |
| Inoue, I | 1 |
| Kawagoe, T | 1 |
| Kitagawa, H | 1 |
| Chang, H | 1 |
| Fujita, T | 1 |
| Muto, S | 2 |
| Imai, M | 2 |
| Asano, Y | 3 |
| Ookawara, S | 1 |
| Tabei, K | 1 |
| Sakurai, T | 1 |
| Sakairi, Y | 1 |
| Furuya, H | 1 |
| Okamoto, T | 1 |
| Marukawa, S | 1 |
| Hayami, H | 1 |
| Ozaki, K | 1 |
| Ishida, H | 1 |
| Kono, K | 1 |
1 review available for nafamostat and Hyperkalemia
| Article | Year |
|---|---|
Mechanisms of hyperkalemia caused by nafamostat mesilate.
Topics: Animals; Benzamidines; Guanidines; Humans; Hyperkalemia; Kidney Tubules, Collecting; Potassium; Seri | 1995 |
8 other studies available for nafamostat and Hyperkalemia
| Article | Year |
|---|---|
Incidence and risk factors for hyperkalaemia in patients treated for COVID-19 with nafamostat mesylate.
Topics: Benzamidines; COVID-19 Drug Treatment; Dexamethasone; Guanidines; Humans; Hyperkalemia; Incidence; P | 2022 |
Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study.
Topics: Antiviral Agents; Benzamidines; COVID-19 Drug Treatment; Guanidines; Humans; Hyperkalemia; Retrospec | 2022 |
A Synthetic Serine Protease Inhibitor, Nafamostat Mesilate, Is a Drug Potentially Applicable to the Treatment of Ebola Virus Disease.
Topics: Animals; Antiviral Agents; Benzamidines; Disseminated Intravascular Coagulation; Ebolavirus; Factor | 2015 |
Brugada-like electrocardiographic pattern due to hyperkalemia.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Brugada Syndrome; Electroc | 2009 |
Hyperkalemia due to nafamostat mesylate.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Guanidines; Humans; Hype | 1995 |
Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct.
Topics: Animals; Benzamidines; Benzoates; Biological Transport, Active; Dose-Response Relationship, Drug; El | 1994 |
Additional mechanisms of nafamostat mesilate-associated hyperkalaemia.
Topics: Adult; Benzamidines; Benzoates; Erythrocytes; Guanidines; Humans; Hyperkalemia; In Vitro Techniques; | 1996 |
[Effect of nafamostat mesilate on the renin-aldosterone system].
Topics: Benzamidines; Guanidines; Humans; Hyperkalemia; Middle Aged; Renin-Angiotensin System | 1992 |